Secreted phospholipase A(2) as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue.
Polymer-coated liposomes can act as versatile drug-delivery systems due to long vascular circulation time and passive targeting by leaky blood vessels in diseased tissue. We present an experimental model system illustrating a new principle for improved and programmable drug-delivery, which takes advantage of an elevated activity of secretory phospholipase A(2) (PLA(2)) at the diseased target tissue. The secretory PLA(2) hydrolyses a lipid-based proenhancer in the carrier liposome, producing lyso-phospholipids and free fatty acids, which are shown in a synergistic way to lead to enhanced liposome destabilization and drug release at the same time as the permeability of the target membrane is enhanced. Moreover, the proposed system can be made thermosensitive and offers a rational way for developing smart liposome-based drug delivery systems. This can be achieved by incorporating specific lipid-based proenhancers or prodestabilisers into the liposome carrier, which automatically becomes activated by PLA(2) only at the diseased target sites, such as inflamed or cancerous tissue.
Davidsen
Jesper
J
Department of Pharmaceutics, The Royal Danish School of Pharmacy, Copenhagen, Denmark.
Jørgensen
Kent
K
Andresen
Thomas L
TL
Mouritsen
Ole G
OG
D000818:Animals; D004337:Drug Carriers; D008081:Liposomes; D010599:Pharmacokinetics; D010741:Phospholipases A / Q000378:metabolism*; D013696:Temperature
D004337:Drug Carriers; D008081:Liposomes; D010741:Phospholipases A